Archive for November 2020
Opposition grows to SBA’s PPP loan forgiveness questionnaire
The SBA’s rollout of the documentation may have run afoul of federal laws on rulemaking, one group said. Read More
Read MoreNewton-based leading producer of jigsaw puzzles acquired
Newton-based Ceaco is the second-largest producer of jigsaw puzzles in America. Read More
Read MoreOp-ed: The return of vinyl … if it ever really left
No longer do vinyl records belong in the realm of snobby aficionados who swear the sound of a record is better than anything else. Read More
Read MoreUniQure’s hemophilia drug shows benefit over Pfizer’s
UniQure’s head of research, Ricardo Dolmetsch, said the results were “functionally curative." Read More
Read MoreTJX plans to roll out e-commerce site for HomeGoods
The company had a lower-than-expected sales decline in Q3. Read More
Read MoreEditorial: The world benefits from Mass. support of life sciences
This week’s good news out of Moderna regarding a Covid vaccine should serve to remind skeptics that the Massachusetts Life Sciences Center is doing more than just cheerleading for local jobs. Read More
Read MoreThe Williams way: Why elite liberal arts colleges are ducking higher ed’s headwinds
It’s the latest example of how Covid-19 is exacerbating the divide between the nation’s wealthiest schools and less well-resourced institutions, enabling those who can afford it to maintain steady operations as the pandemic persists. Read More
Read MoreExpert View: How Covid-19 is shaking up college admissions for the 2021 school year
The good news: More students should be on the receiving end of early-action and early-decision admissions this year as schools scramble to offset losses tied to Covid-19. Read More
Read MoreKing Street plans $500M biomanufacturing campus in Devens
The five-building campus will be the first project in the Boston life-science development company’s new business line, called Pathway. Read More
Read MoreFidelity stocks up on Moderna, surpassing Flagship as the largest shareholder
The Cambridge biotech’s stock price has skyrocketed this year due to the development of its Covid-19 vaccine. Read More
Read More